Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design

Abstract

Background and aims Gallbladder carcinoma is a rare, aggressive malignancy of the biliary tract associated with a poor prognosis. Despite the deployment of targeted therapies that have demonstrated marked survival benefits in many tumor types, traditional cytotoxic chemotherapy has remained the mainstay of treatment for unresectable and metastatic gall-bladder cancer. Methods Systematic review of ongoing and prior clinical studies shows a paucity of biomarker-driven therapeutic trials using targeted agents in gallbladder cancer. In fact, over the past 6 years, of the 38 therapeutic biliary tract protocols listed on clinicaltrials.gov, only 6 (21 %) utilized targeted therapies based upon tumor biomarkers or genomics. Now that we have entered the era of next-generation sequencing and precision medicine, we are beginning to identify common and specific genetic alterations in gallbladder carcinomas. Results A review of the literature reveals alterations in ARID1A, BRAF, CDKN2A/B, EGFR, ERBB2-4, HKN-RAS, PIK3CA, PBRM1, and TP53. Given the widespread use of tumor genomic profiling and the fact that most of the aforementioned alterations are pharmacologically tractable, these observations suggest the potential for new therapeutic strategies in this aggressive malignancy. Conclusions Taken together, further understanding of the genomic landscape of gallbladder cancer coupled with biomarker-driven clinical trials that match therapies to targets are urgently needed.

XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer

“…These above reasons make the prognosis of GBC unsatisfactory. Although many biological marks have been studied, no one can accurately diagnose GBC and predict patients' survival (Sicklick et al, 2016;Sharma et al, 2017). Therefore, discovering reliable early diagnostic biomarkers and exploring the mechanism of treatment resistance are critically important to improve the prognosis of GBC.…”

Educational Case: Incidental Gallbladder Adenocarcinoma

“…12 Different agents against molecular mutations targeting therapy are being tried, although there is dismal improvement in the survival of patients with GBC. 13,14 Most recently, the role of DNA methylation in GBC is being studied for clinical implication and future prospects of biomarker development for early diagnosis and therapeutic interventions. 15 What Is Known About The Metastatic Features of the GB Carcinoma?…”

A hindsight reflection on the clinical studies of poly(l‐glutamic acid)‐paclitaxel

“…Although cathepsin B and estrogen levels have been hinted to be important regulators for the function of PG‐TXL, none of the clinical trials enrolled patients according to the two indexes, which may have contributed to the failure of PG‐TXL. Fortunately, with the current development of genome sequencing, future clinical studies will have the opportunities to target the correct patient population with greater accuracy . It is worth noting, however, that credits should not be taken away from the hard‐working researchers and clinicians involved in the clinical trials of PG‐TXL.…”